|
WO2020198062A1
|
|
Pharmaceutical compounds for the treatment of complement mediated disorders
|
|
WO2020131974A1
|
|
Targeted dosing for the treatment of complement mediated disorders
|
|
AU2019346464A1
|
|
Morphic forms of complement factor D inhibitors
|
|
WO2020051532A2
|
|
Macrocyclic compounds for the treatment of medical disorders
|
|
WO2020051538A1
|
|
Morphic forms of complement factor d inhibitors
|
|
US2019382376A1
|
|
Pharmaceutical compounds for treatment of medical disorders
|
|
WO2020041301A1
|
|
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
|
EP3814374A1
|
|
Complement alternative pathway-associated nephropathy biomarkers
|
|
US2019038623A1
|
|
Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
|
|
EP3589628A1
|
|
Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
|
|
WO2018160892A1
|
|
Macrocyclic compounds for treatment of medical disorders
|
|
AU2017290593A1
|
|
Quinazoline and indole compounds to treat medical disorders
|
|
BR112018006206A2
|
|
composition, use of a combination, pharmaceutical fixed dosage form, fixed dosage combination, packaging, and use of a fixed dose combination
|
|
US2017056428A1
|
|
Compounds for the treatment of medical disorders
|
|
WO2017035417A1
|
|
Phosphonate compounds for treatment of immune and inflammatory disorders
|
|
WO2017035401A1
|
|
Amide compounds for treatment of immune and inflammatory disorders
|
|
WO2017035362A1
|
|
Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
|
|
WO2017035348A1
|
|
Alkyne compounds for treatment of medical disorders
|
|
WO2017035411A1
|
|
Ether compounds for treatment of immune and inflammatory disorders
|
|
EP3340982A1
|
|
Compounds for treatment of immune and inflammatory disorders
|
